


RESEARCH ARTICLE

Open Access



Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study

Marta Ruiz-Algueró¹, Victoria Hernando¹, Henar Marcos², Gonzalo Gutiérrez³, Maria Jesus Pérez-Elías⁴, Juan Carlos López-Bernaldo de Quirós⁵, Federico Pulido⁶, Miguel Górgolas⁷, Jesus Sanz⁸, Ines Suarez-García^{9,10}, Maria Teresa Fernandez¹¹, Juan Emilio Losa¹², Jose Luis Pérez¹³, Maria Oliva Ladrero¹⁴, Miguel Ángel Prieto¹⁵, Gustavo González¹⁶, Ana Izquierdo¹⁷, Luis Javier Viloria¹⁸, Irene López¹⁹, Eva Martínez²⁰, Daniel Castrillejo²¹, Rosa Aranguren²², Maria Antonia Belmonte²³, I V Aranda-García²⁴, Antonio Arraiza²⁵, Asuncion Diaz^{1*}  and on behalf of the Hospital Survey Study Group

Abstract

Background: HIV infection has become a chronic disease and well-being of people living with HIV (PLHIV) is now of particular concern. The objectives of this paper were to describe self-rated health among PLHIV, on ART and on ART virally suppressed and to analyse its determinants.

Methods: Data were obtained from a second-generation surveillance system based on a cross-sectional one-day survey in public hospitals. Epidemiological and clinical data were collected among HIV-infected inpatients and outpatients receiving HIV-related care the day of the survey in 86 hospitals in 2019. Self-rated health was measured using a question included in the National Health Survey: "In the last 12 months, how would you rate your health status?" an ordinal variable with five categories (very good, good, moderate, bad and very bad). For the analysis, these responses were dichotomized into two categories: 1 = very good/good and 0 = moderate, bad or very bad health status. Factors associated with very good/good self-rated health were estimated using logistic regression.

Results: Of 800 PLHIV, 67.5% perceived their health as very good/good, 68.4% among PLHIV on ART and 71.7% of those virally suppressed. Having university education (adjusted odds ratio (aOR):2.1), being unemployed (aOR:0.3) or retired (aOR:0.2), ever being diagnosed of AIDS (aOR:0.6), comorbidities (aOR:0.3), less than 2 year since HIV diagnosis (aOR:0.3) and not receiving ART (aOR:0.3) were associated with good self-rated health. Moreover, among PLHIV on ART, viral load less than 200 copies (aOR:3.2) were related to better perceived health. Bad adherence was inversely associated with good self-rated health among PLHIV on ART (aOR:0.5) and of those virally suppressed (aOR:0.4).

Conclusions: Nearly seven in 10 PLHIV in Spain considered their health status as very good/good, being higher among virally suppressed PLHIV. Both demographic and clinical determinants affect quality of life.

Keywords: Self-rated health, Health quality of life, Fourth 90, People living with HIV, Spain

* Correspondence: adiaz@isciii.es

¹Unidad de vigilancia de VIH, ITS y hepatitis, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, C/ Monforte de Lemos, 5, 28029 Madrid, Spain

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Highly effective antiretroviral treatment (ART) has dramatically changed the natural history of HIV infection in terms of decreasing mortality and increasing life expectancy, thus the HIV infection has become a chronic disease [1]. Benefits of ART go beyond the individual level, since suppressing viral load substantially reduces the risk of HIV transmission [2].

In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 90–90–90 strategy. This target directed efforts towards testing and treatment in order to achieve the goal of 90% of people living with HIV (PLHIV) being diagnosed, 90% of those diagnosed receiving ART and 90% of those receiving ART having viral load suppression, i.e., at least 73% of all PLHIV worldwide being virally suppressed [3]. Two years later, the World Health Organization (WHO) included the 90–90–90 target in their Global Health Sector Strategy for 2016–2021 to end the acquired immunodeficiency syndrome (AIDS) epidemic as a public health threat by 2030, along with other intermediate objectives to be achieved in 2020. Furthermore, the overall goal included ensuring that PLHIV had healthy lives and promoting well-being for all at all ages [4]. In the same year, Lazarus *et al.* proposed the concept of the “fourth 90”, with the objective of operationalizing the WHO goal of promoting well-being. The fourth 90 set the objective that 90% of PLHIV with viral load suppression have a good health-related quality of life (HRQoL) [5].

There is no consensus on how to measure HRQoL among PLHIV. Different instruments have been used for this purpose, both generic and HIV-specific scales, that explore different domains [6]. Generic scales have the benefit of allowing data comparisons with the general population [7]; however, they may be less sensitive to changes among the HIV infected population. HIV-specific scales might solve this problem due to their consistency and validity among PLHIV [6]. A recent study in Spain has validated the Spanish version of the WHOQOL-HIV-BREF in a broad sample of HIV-infected people [8]. However, HRQoL measurement with these tools is time-consuming and difficult to incorporate into clinical practice [9].

Self-rated health is a consolidated indicator related to well-being and quality of life [10]. It is considered a predictor of morbidity, mortality and health services use [11, 12] and has been widely used in health and socioeconomic surveys at population level in Europe (for instance, in Denmark, Germany, Ireland, Italy, Iceland and Norway) [13, 14].

Several studies have used self-rated health to measure quality of life among PLHIV [15] and PLHIV on ART [16, 17], and have identified related epidemiological and clinical variables. Self-perceived health and comorbidities

have been suggested as the two main domains of good HRQoL of PLHIV or “fourth 90” [5]. In the beginning, this new target was described as the last stage of the HIV continuum of care, applied only to PLHIV who were on ART and virally suppressed. However, there is an open debate about whether good HRQoL should be a target only for PLHIV who are virally suppressed or whether it should also cover the previous 90–90–90 and therefore encompass the whole HIV continuum of care [18].

In 2019, between 120,000 and 180,000 people were estimated to be living with HIV in Spain; the estimated HIV prevalence in the age group 15 to 49 years (0.4%) was higher than in other European countries with similar concentrated epidemics, such as France (0.3%) or Italy (0.2%) [19]. At the end of 2019, it was estimated 87% of PLHIV were diagnosed, 97.3% of those diagnosed were receiving ART and 90.4% of those receiving ART having viral load suppression [20]. Recently, several studies have been published exploring HRQoL of PLHIV in Spain, overall and by gender, using HIV-specific scales [8, 21]. However, to our knowledge, there are no studies that analyse self-reported health among PLHIV.

Our aim was to describe self-rated health among PLHIV, among those on ART, and among those on ART that are virally suppressed, and to evaluate factors associated with very good/good self-rated health among these groups in Spain.

Methods

An observational study was carried out. Data were obtained from a second-generation surveillance system of PLHIV, in Spanish referred to as “Encuesta hospitalaria de pacientes infectados con VIH (EH)” [Hospital survey of patients infected with HIV]. A description of its methodology has been published elsewhere [22]. Briefly, the EH is a cross-sectional survey carried out annually on a specific day. Epidemiological, behavioural and clinical variables were collected among all PLHIV, inpatients and outpatients, attending general public hospitals for HIV-related care on the day of the survey. This population-based information system started in 1996 and over time, variables have been modified to include other information of interest. In the 2019 edition, a question on self-rated health status was introduced. The study was performed in public hospitals. In Spain, HIV care is hospital-based, ART is exclusively provided within hospital pharmacies and HIV-infected subjects living in the catchment area of a public hospital receive care at that hospital. Due to these catchment areas are defined at geographical level and the covered population is known, it is possible to estimate the coverage of the study. ‘Population coverage’ was defined as the total population included in the participating hospitals’

catchment area divided by the total population living in the participating regions. 'Survey coverage' was calculated as the total population living in the participating hospitals' catchment area divided by the total population in Spain.

Participation in the survey is voluntary for both hospitals and individual patients. In 2019 the number of participating hospitals was 86 out of 143 eligible (60.1%) from 15, out of the 19 autonomous regions in Spain. Participating regions were the following (by alphabetical order): Aragón, Asturias, Baleares, Canarias, Cantabria, Castilla-La Mancha, Castilla y León, Ceuta, Comunidad de Madrid, Comunidad Valenciana, Extremadura, Melilla, Murcia, La Rioja and País Vasco (population coverage: 65.5% of the total population in the participating regions). Survey coverage was 38.5% of the whole Spanish population.

Variables were collected from each HIV patient using a standard questionnaire by inpatient and outpatient medical staff. All study variables were extracted from the clinical records, except demographic and self-rated health data, which were obtained directly from the patients by the attending physician. Once completed, the questionnaires were sent to the National Centre of Epidemiology (coordinating center), where questionnaires were entered into a database, made quality control and data analysis.

Variables included in this analysis were the following: a) epidemiological: gender, age, educational level, country of birth, residence, employment status, HIV transmission mode, b) clinical: HIV stage, viral load and CD4 count at last measurement, being on ART, ART adherence, years since HIV diagnosis and comorbidities. ART adherence was classified as optimal, suboptimal or very bad according to the judgment of the attending physician. Comorbidity was gathered as a dichotomous variable that collects the presence of non-AIDS diseases in the previous 12 months (cancer, heart disease, cerebrovascular disease, active hepatitis C, liver cirrhosis, hypertension, mental disorder, kidney disease, respiratory disease).

Self-rated health was measured using the same question included in the last National Health Survey in Spain [23]: "In the last 12 months, how would you rate your health status?" with five response options: very good, good, moderate, bad and very bad. For the analysis, we grouped this variable into two categories: 1 = very good/good and 0 = moderate, bad or very bad health status.

We conducted a descriptive, bivariate and multivariate analysis, according to variables of interest, among all participants, participants on ART and participants on ART virally suppressed. For quantitative variables, median and interquartile range (IQR) were used. For categorical variables, frequency distributions were

calculated and the chi-squared test was used to compare percentages. We calculated prevalence of very good/good self-rated health and its 95% confidence interval (95% CI). Logistic regression models were fitted using a backward elimination procedure. Associations were measured using the odds ratio (OR) and its 95% CI. Data analyses were performed using the STATA statistical software package Version 14 (Stata Corp, College Station, Texas, USA).

Results

In 2019, a total of 843 PLHIV were included in the study. Of these, 800 (94.9%) had data available on self-rated health. Regarding recruitment area, 713 (89.1%) of participants were outpatients, 79 (9.9%) were inpatients and in the remaining 8 subjects (1.0%) this information was unknown. Characteristics of the study population are shown in Table 1. The majority were male, had been born in Spain and were men infected through sexual contact with men (MSM). Median age was 51 years (IQR: 43–56) and 37.4% were between 51 and 60 years old. Nearly 41% had a low educational level (2.5% had no studies and 38.4% only primary education). Regarding residence and employment status, more than half were living with their family and had been employed for the 30 days before the study. Participants had been diagnosed with HIV a median of 14 (IQR: 6–23) years ago. Overall, 776 cases (97.0%) were on ART and of these, 702 (90.5%) had a viral load less than 200 copies/ml at last measurement. Among the 24 cases who were not receiving ART at the time of the study, treatment had been delayed in 15 patients for medical reasons, and the reason was unknown for the remaining cases. The percentage of subjects with a CD4 T-cell count greater than 349 cells was 76.8%. Overall, 11% had other comorbidities and the percentage ever diagnosed with AIDS was 33.4% (267 cases).

According to self-rated health, 24.1% considered their health as very good, 43.4% good, 19.8% as moderate and 8.6 and 4.1% bad and very bad, respectively.

Prevalence of very good or good self-rated health according to the epidemiological and clinical characteristics is presented in Table 2. Among all patients, this percentage was 67.5%. Prevalence of very good or good self-rated health increased with educational level, and was higher in cases born in countries other than Spain (75.0%) and employed patients (82.1%). Conversely, prevalence of very good/good self-rated health was lower among older age groups and among people who had ever injected drugs (PWID/Ex-PWID) (51.8%), people who lived in closed institutions, prisons or were homeless (35.5%), were unemployed or retired/disabled (47%), and among those diagnosed more than 20 years ago (60.2%). Regarding clinical variables, prevalence of very

Table 1 Characteristics of study population and by self-rated health perception, 2019

Variables	Total cases		Self-rated health perception									
			Very good		Good		Moderate		Bad		Very bad	
	n	%	n	%	n	%	n	%	n	%	n	%
Gender												
Male	591	73.9	141	73.1	263	75.8	116	73.4	51	73.9	20	60.6
Female	195	24.4	47	24.4	80	23.1	40	25.3	16	23.2	12	36.4
Transgender	12	1.5	4	2.1	4	1.2	2	1.3	1	1.4	1	3.0
Unknown	2	0.3	1	0.5	0	0.0	0	0.0	1	1.4	0	0.0
Age group (years)												
< 35	111	13.9	48	24.9	38	11.0	17	10.8	5	7.2	3	9.1
35–50	282	35.3	68	35.2	129	37.2	52	32.9	24	34.8	9	27.3
51–60	299	37.4	55	28.5	133	38.3	69	43.7	27	39.1	15	45.5
> 60	95	11.9	16	8.3	44	12.7	17	10.8	13	18.8	5	15.2
Unknown	13	1.6	6	3.1	3	0.9	3	1.9	0	0	1	3.0
Educational level												
Illiteracy	20	2.5	1	0.5	7	2.0	5	3.2	3	4.3	4	12.1
Primary education	307	38.4	49	25.4	132	38.0	72	45.6	39	56.5	15	45.5
Secondary education	258	32.2	74	38.3	109	31.4	52	32.9	15	21.7	8	24.2
University education	180	22.5	62	32.1	88	25.4	22	13.9	7	10.1	1	3.0
Unknown	35	4.4	7	3.6	11	3.2	7	4.4	5	7.2	5	15.2
Country of birth												
Spain	631	78.9	137	71.0	275	79.3	133	84.2	60	87.0	26	78.8
Other	164	20.5	56	29.0	67	19.3	25	15.8	9	13.0	7	21.2
Unknown	5	0.6	0	0	5	1.4	0	0	0	0	0	0.0
Residence												
Living with family	478	59.8	116	60.1	214	61.7	96	60.8	34	49.3	18	54.5
Living alone	216	27.0	55	28.5	87	25.1	42	26.6	24	34.8	8	24.2
Closed institutions	17	2.1	1	0.5	5	1.4	7	4.4	3	4.3	1	3.0
Prisons	9	1.1	1	0.5	4	1.2	1	0.6	3	4.3	0	0.0
Homeless	5	0.6	0	0.0	0	0.0	2	1.3	1	1.4	2	6.1
Other	70	8.8	19	9.8	37	10.7	7	4.4	4	5.8	3	9.1
Unknown	5	0.6	1	0.5	0	0.0	3	1.9	0	0.0	1	3.0
Employment status												
Employed	430	53.8	142	73.6	211	60.8	59	37.3	15	21.7	3	9.1
Unemployed	139	17.4	23	11.9	42	12.1	39	24.7	19	27.5	16	48.5
Retired/disabled	184	23.0	19	9.8	67	19.3	56	35.4	29	42.0	13	39.4
Student	23	2.9	7	3.6	13	3.7	2	1.3	1	1.4	0	0.0
Other/ unknown	24	3.0	2	1.0	14	4.0	2	1.3	5	7.3	1	3.0
Mode of transmission												
Heterosexuals	246	30.8	65	33.7	106	30.5	41	25.9	22	31.9	12	36.4
MSM	293	36.6	83	43.0	145	41.8	44	27.8	17	24.6	4	12.1
PWID	195	24.4	29	15.0	72	20.7	58	36.7	25	36.2	11	33.3
Other/unknown	66	8.3	16	8.3	24	6.9	15	9.5	5	7.3	6	18.2
Total	800	100	193	100	347	100	158	100	69	100	33	100

MSM Men who have sex with men, PWID People who injected drugs

Table 2 Prevalence of very good/good self-rated health among all PLHIV, PLHIV on antiretroviral treatment and PLHIV on antiretroviral treatment virally suppressed

	All PLHIV		Very good/good self-rated health among all PLHIV		On ART		Very good/good self-rated health among PLHIV on ART		On ART virally suppressed		Very good/good self-rated health among PLHIV on ART virally suppressed	
	n	n	% (95% CI)	n	n	% (95% CI)	n	n	% (95% CI)			
Gender												
Male	591	404	68.4 (64.4–72.1)	571	398	69.7 (65.8–73.4)	516	377	73.1 (69.0–76.8)			
Female	195	127	65.1 (58.0–71.8)	193	126	65.3 (58.1–72.0)	177	120	67.8 (60.4–74.6)			
Transgender	12	8	66.7 (34.9–90.0)	11	7	63.6 (30.8–89.1)	8	6	75.0 (34.9–96.8)			
Unknown	2	1	50.0 (1.3–98.7)	1	0	0	1	0	0			
Age group (years)												
< 35	111	86	77.5 (68.6–84.9)	103	82	79.6 (70.5–86.9)	91	73	80.2 (70.6–87.8)			
35–50	282	197	69.9 (64.1–75.2)	274	194	70.8 (65.0–76.1)	240	182	75.8 (69.9–81.1)			
51–60	299	188	62.9 (57.1–68.4)	295	187	63.4 (57.6–68.9)	274	182	66.4 (60.5–72.0)			
> 60	95	60	63.2 (52.6–72.8)	92	60	65.2 (54.6–74.9)	87	59	67.8 (56.9–77.4)			
Unknown	13	9	69.2 (38.6–90.9)	12	8	66.7 (34.9–90.1)	10	7	70.0 (34.8–93.3)			
Educational level												
Illiteracy/Primary education	327	189	57.8 (52.2–63.2)	319	188	58.9 (53.3–64.4)	285	176	61.8 (55.8–67.4)			
Secondary education	258	183	70.9 (65.0–76.4)	252	180	71.4 (65.4–76.9)	229	172	75.1 (69.0–80.6)			
University education	180	150	83.3 (77.1–88.5)	171	146	85.4 (79.2–90.3)	159	139	87.4 (81.2–92.1)			
Unknown	35	18	51.4 (34.0–68.6)	34	17	50.0 (32.4–67.6)	29	16	55.2 (35.7–73.6)			
Country of birth												
Spain	631	412	65.3 (61.4–69.0)	613	406	66.2 (62.3–70.0)	566	390	68.9 (64.9–72.7)			
Other	164	123	75.0 (67.7–81.4)	158	120	76.0 (68.5–82.4)	132	109	82.6 (75.0–88.6)			
Unknown	5	5	100.0 (–)	5	5	100 (48.0–100)	4	4	100 (39.8–100)			
Residence												
Living with family	478	330	69.0 (63.4–71.9)	467	326	69.8 (65.4–73.9)	428	309	72.2 (67.7–76.4)			
Living alone	216	142	65.7 (59.0–72.0)	208	139	66.8 (60.0–73.2)	188	136	72.3 (65.4–78.6)			
Closed institutions/Prison/ Homeless	31	11	35.5 (19.2–54.6)	31	11	35.5 (19.2–54.6)	25	9	36.0 (18.0–57.5)			
Other	70	56	80.0 (68.7–88.6)	65	54	83.1 (71.7–91.2)	59	48	81.4 (69.1–90.3)			
Unknown	5	1	20.0 (0.5–71.6)	5	1	20.0 (0.5–71.6)	2	1	50.0 (1.2–98.7)			
Employment status												
Employed	430	353	82.1 (78.1–85.6)	421	348	82.7 (78.7–86.2)	389	333	85.6 (81.7–88.9)			
Unemployed	139	65	46.8 (38.3–55.4)	126	61	48.4 (39.4–57.5)	105	54	51.4 (41.5–61.3)			
Retired/disabled	184	86	46.7 (39.4–54.2)	182	86	47.2 (39.8–54.8)	167	82	49.1 (41.3–56.9)			
Student	23	20	87.0 (66.4–97.2)	23	20	87.0 (66.4–97.2)	22	19	86.4 (65.1–97.1)			
Other/ unknown	24	16	66.7 (44.7–84.4)	24	16	66.7 (44.7–84.4)	19	15	78.9 (54.4–93.9)			
Mode of transmission												
Heterosexual	246	171	69.5 (63.3–75.2)	240	168	70.0 (63.8–75.7)	216	161	74.5 (68.2–80.2)			
MSM	293	228	77.8 (72.6–82.4)	282	223	79.1 (73.9–83.7)	260	210	80.8 (75.4–85.4)			
PWID	195	101	51.8 (44.5–59.0)	192	101	52.6 (45.3–59.8)	169	95	56.2 (48.4–63.8)			
Other/ unknown	66	40	60.6 (47.8–72.4)	62	39	62.9 (49.7–74.8)	57	37	64.9 (51.1–77.1)			
HIV infection stage												
Asymptomatic	386	299	77.5 (73.0–81.5)	378	296	78.3 (73.8–82.4)	353	280	79.3 (74.7–83.4)			
Symptomatic non AIDS	126	80	63.5 (54.4–71.9)	122	77	63.1 (53.9–71.7)	111	72	64.9 (55.2–73.7)			
AIDS	267	144	53.9 (47.8–60.0)	257	143	55.6 (49.3–61.8)	224	141	63.0 (56.3–69.3)			
Unknown	21	17	80.9 (58.1–94.6)	19	15	78.9 (54.4–93.9)	14	10	71.4 (41.9–91.6)			

Table 2 Prevalence of very good/good self-rated health among all PLHIV, PLHIV on antiretroviral treatment and PLHIV on antiretroviral treatment virally suppressed (Continued)

	All PLHIV		Very good/good self-rated health among all PLHIV		On ART		Very good/good self-rated health among PLHIV on ART		On ART virally suppressed		Very good/good self-rated health among PLHIV on ART virally suppressed	
	n		n	% (95% CI)	n		n	% (95% CI)	n		n	% (95% CI)
Viral load < 200 copies/ml (last determination)												
Yes	704		503	71.4 (68.0–74.8)	702		503	71.6 (68.2–75.0)	–		–	–
No	71		24	33.8 (23.0–46.0)	56		17	30.4 (18.8–44.0)	–		–	–
Unknown	25		13	52.0 (31.3–72.2)	18		11	61.1 (35.7–82.7)	–		–	–
CD4 count (last determination)												
< 200	67		14	20.9 (11.9–32.6)	61		12	19.7 (10.6–31.8)	36		10	27.8 (14.2–45.2)
200–349	92		48	52.2 (41.5–62.7)	89		47	52.8 (51.9–63.5)	76		91	59.2 (47.3–70.4)
350–499	116		71	61.2 (51.7–70.1)	112		68	60.7 (51.0–69.8)	99		60	60.6 (50.2–70.3)
> =500	499		391	78.4 (74.5–81.9)	496		391	78.8 (75.0–82.3)	483		381	78.9 (75.0–82.4)
Unknown	26		16	61.5 (40.6–79.8)	18		13	72.2 (46.5–90.3)	8		7	87.5 (47.3–99.7)
Comorbidities												
Yes	88		29	33.0 (23.3–43.8)	87		29	33.3 (23.6–44.3)	72		27	37.5 (26.4–49.7)
No/ Unknown	712		511	71.8 (66.3–75.0)	689		502	72.9 (69.3–76.1)	630		476	75.6 (72.0–78.9)
Antiretroviral treatment												
Yes	776		531	68.4 (65.0–71.7)	–		–	–	–		–	–
No	18		8	44.4 (21.5–69.2)	–		–	–	–		–	–
Unknown	6		1	16.7 (0.4–64.1)	–		–	–	–		–	–
Adherence												
Optimal	653		471	72.1 (68.5–75.5)	653		471	72.1 (68.5–75.5)	611		451	73.8 (70.1–77.3)
Suboptimal	68		36	52.9 (40.4–65.1)	68		36	52.9 (40.4–65.2)	56		31	55.4 (41.5–68.7)
Very bad	25		3	12.0 (2.5–31.2)	25		3	12.0 (2.5–31.2)	8		1	12.5 (3.2–52.7)
Unknown	30		21	70.0 (50.6–85.2)	30		21	70.0 (50.6–85.3)	27		20	74.1 (53.7–88.9)
No/unknown ART	24		9	37.5 (18.8–59.4)	–		–	–	–		–	–
Years since HIV diagnosis												
< 2	73		42	57.5 (45.4–69.0)	59		34	57.6 (44.1–70.4)	38		27	71.1 (54.1–84.6)
2–5	111		86	77.5 (68.6–84.8)	109		86	78.9 (70.0–86.1)	99		81	81.8 (72.3–88.6)
6–10	121		93	76.9 (68.3–84.0)	120		93	77.5 (69.0–84.6)	110		89	80.9 (72.3–87.8)
11–15	111		77	69.4 (59.9–77.8)	110		77	70.0 (60.5–78.4)	104		75	72.1 (62.5–80.5)
> 15	374		233	62.3 (57.2–67.2)	369		233	63.1 (58.0–68.1)	345		225	65.2 (60.0–70.2)
Unknown	10		9	90.0 (55.5–99.7)	9		8	88.9 (51.7–99.7)	6		6	100 (54.1–100)
Total	800		540	67.5 (64.1–70.7)	776		531	68.4 (65.0–71.7)	702		503	71.7 (68.2–75.0)

95% CI Confidence interval 95%, PLHIV People living with HIV, ART antiretroviral treatment, MSM Men who have sex with men, PWID People who injected drugs

good or good self-rated health was lower among those ever diagnosed of AIDS (53.9%), patients with viral load more than 200 copies (33.8%) or low CD4 count (20.9%), with comorbidities (33.0%) and not receiving ART (44.4%). All analyzed variables, except gender, were significantly associated with health status in the bivariate analysis ($p < 0.05$).

Among subjects on ART and those who were on ART and virally suppressed, prevalence of very good or good self-rated health was 68.4 and 71.7%, respectively. Differences in prevalence by variables of interest between these two groups were similar to overall cases.

Additionally, this prevalence was higher in patients with optimal ART adherence (Table 2).

In the multivariate analysis, three regression logistic models, adjusted by gender, age, country of birth and transmission mode, were fitted (Table 3). Among PLHIV, having university education was positively associated with having very good or good self-rated health. Factors associated with a poor evaluation of their health status were being unemployed or retired, living in closed institutions/prison/being homeless, ever having been diagnosed of AIDS, having comorbidities, not being on ART and having been diagnosed with HIV less than 2

years ago. Among people on ART, determinants related to reporting better health were similar to those found among overall PLHIV. Moreover, having a viral load less than 200 copies/ml was also associated with good/very good self-rated health. Finally, among cases on ART and those on ART and virally suppressed, suboptimal/very bad adherence to ART were associated with poor self-rated health.

Discussion

This manuscript presented data on self-rated health among PLHIV in Spain. Our findings showed the impact of socio-demographic and clinical factors on perceived health. To our knowledge, this is the first study in Spain that provides population-based information on self-rated health using a second generation HIV surveillance system as data source.

Overall, 67.5% of PLHIV perceived their health as very good or good in the previous 12 months. This percentage was 68.4 and 71.7% among PLHIV on ART, and on ART and virally suppressed, respectively. These figures were lower than the 74% reported among the general population by the National Health Survey in Spain, 2017. This difference could be partly explained by the fact that the mean age of analysed PLHIV was higher than the general population included in the Spanish National Health Survey (49 years vs. 43 years, respectively); in fact, positive health perceptions decreased with increasing age in the National Health Survey [23].

Our result was lower than reported in the United Kingdom in 2017 (73% of PLHIV reported very good or good self-rated health) [15] and in South Africa in 2012 (74.1%) [24], although was higher than the 63% reported in Sweden [25]. The United Kingdom study also found a lower prevalence of good/very good self-rated health in PLHIV than in the general population in England (76%) [15]. Among PLHIV on ART, we obtained higher figures than described in Brazil in 2009 (66.4%) [26] and in 2011 (65.0%) [17] in this same subgroup. However, different characteristics of HIV epidemics between countries make the comparisons difficult.

Similarly to other studies in Spain [8, 27] and abroad [17, 28], educational level and employment status were strongly associated with self-rated health in PLHIV, in both ART treated and virologically suppressed. Both variables have been considered a proxy of socio-economic status, which has been shown to be associated with self-rated health among the general population in Spain [23]. Lack of financial and educational resources could increase uncertainty under life circumstances, impairing quality of life. In a cross-sectional study among PLHIV in Canada, a great impact of employment status was found on both physical and mental health quality of life and the authors suggested a bidirectional relationship between both variables: a higher quality of life would be necessary to maintain employment and employment might be a benefit of health and well-being [29]. In our study, being retired was also associated with poor self-

rated health suggesting that a person's financial situation was an important determinant [8].

Lower percentage of very good/good self-rated health was reported among PLHIV who lived in closed institutions, or prisons and those who were homeless. Other studies have described associations between homeless or marginally-housed PLHIV and poor access and adherence to ART, as well as poor retention in care, highlighting the vulnerability of this group of people [30]. On the other hand, lack of social support has been linked to poor health status among PLHIV, either as an independent factor or mediated by depression, isolation or marginalization [8, 28, 31, 32].

Regarding disease stage, people who had ever been diagnosed of AIDS rated their health status as poorer. AIDS has been related to worse physical health and lower scores in mental components of HRQoL [17, 28, 32]. Some cases that reached the last stage of HIV infection are long-term survivors who may have experienced the hardest years of the HIV epidemic with less effective treatments or with more side effects. In our study, 51% of total AIDS cases were diagnosed with HIV infection between 1985 and 2000.

Comorbidities are a major determinant of quality of life for PLHIV, both in the physical [33, 34] and psychological domains [31]. We found a lower prevalence of comorbidities than other studies in Spain [35], suggesting that this second-generation surveillance system did not fully capture all the complexity of multi-morbidity in these patients. In spite of this limitation, our results showed that comorbidities had an important impact on self-rated health among PLHIV, even among patients receiving ART and those with viral suppression. As HIV infection become a chronic disease, other comorbidities have emerged and a comprehensive management of these patients should reinforce preventive measures, early detection, and treatment in order to improve their perceived health.

Aging has been associated with worse HQoL [8, 28]. Some studies have reported a greater impact of age on physical than on mental health [32]; other authors have described a lower prevalence of depression and anxiety in older people [31], related to development of resilience and coping strategies [36]. Our results showed a decreased prevalence of good/very good self-rated health with increasing age in the univariate analysis, but it was no longer statistically significant in the multivariate analysis. This suggests that other factors related to aging, such as comorbidities and ever having been diagnosed of AIDS, rather than biological age, could contribute to poor evaluation of health status in older PLHIV.

A longer time with a diagnosed HIV infection has been associated with lower scores of HQoL [8, 36]. In contrast, our results showed that having had an HIV

Table 3 Factors associated with very good/good self-rated health among all PLHIV, PLHIV on antiretroviral treatment and PLHIV on antiretroviral treatment virally suppressed, 2019

	All PLHIV			PLHIV on ART			PLHIV on ART virally suppressed		
	aOR	95% CI	p	aOR	95% CI	p	aOR	95% CI	p
Gender (male)									
Female	0.7	0.4–1.1	0.164	0.7	0.4–1.1	0.105	0.6	0.4–1.0	0.046
Transgender	1.1	0.2–5.5	0.882	0.9	0.1–5.5	0.899	1.4	0.2–10.5	0.744
Age group (< 35)									
35–50	0.8	0.4–1.5	0.409	0.8	0.4–1.6	0.500	1.1	0.5–2.5	0.737
51–60	0.8	0.4–1.6	0.516	0.7	0.3–1.5	0.344	1.1	0.5–2.3	0.901
> 60	1.6	0.7–3.6	0.298	1.4	0.6–3.5	0.459	2.0	0.8–5.3	0.142
Educational level (Illiteracy/Primary education)									
Secondary education	1.1	0.8–1.7	0.509	1.1	0.7–1.7	0.587	1.2	0.8–2.0	0.382
University education	2.1	1.2–3.8	0.010	2.0	1.1–3.7	0.024	2.1	1.1–3.9	0.028
Country of birth (Spain)									
Other	1.4	0.9–2.3	0.180	1.5	0.9–2.5	0.138	1.6	0.9–3.0	0.106
Residence (living with family)									
Living alone	0.7	0.5–1.1	0.133	0.7	0.5–1.1	0.166	0.8	0.5–1.3	0.450
Closed institutions/Prison/Homeless	0.4	0.1–1.0	0.040	0.4	0.2–1.1	0.088	0.3	0.1–0.9	0.039
Other	1.2	0.6–2.5	0.664	1.3	0.6–2.8	0.575	1.1	0.5–2.4	0.868
Employment status (Employed)									
Unemployed	0.3	0.2–0.4	< 0.001	0.3	0.2–0.5	< 0.001	0.2	0.1–0.4	< 0.001
Retired/disabled	0.2	0.1–0.4	< 0.001	0.2	0.1–0.4	< 0.001	0.2	0.1–0.3	< 0.001
Student	2.0	0.5–7.6	0.313	2.1	0.5–8.6	0.290	2.3	0.6–9.2	0.256
Mode of transmission (heterosexual)									
MSM	1.0	0.6–1.7	0.892	0.8	0.5–1.5	0.507	0.7	0.4–1.3	0.248
PWID	0.7	0.4–1.2	0.174	0.7	0.4–1.2	0.206	0.7	0.3–1.1	0.132
Stage (asymptomatic)									
Symptomatic non AIDS	0.7	0.4–1.2	0.254	0.7	0.4–1.2	0.156	0.6	0.4–1.1	0.128
AIDS	0.6	0.4–0.8	0.006	0.6	0.4–0.9	0.023	0.7	0.5–1.2	0.207
Comorbidities (No/Unknown)									
Yes	0.3	0.2–0.6	< 0.001	0.3	0.2–0.6	< 0.001	0.4	0.2–0.7	0.002
Years since HIV diagnosis (> 15)									
< 2	0.3	0.1–0.6	< 0.001	0.3	0.1–0.6	0.001	0.3	0.1–0.8	0.021
2–5	0.6	0.3–1.1	0.126	0.7	0.3–1.4	0.270	0.8	0.4–1.6	0.519
6–10	0.6	0.4–1.2	0.165	0.7	0.4–1.3	0.264	0.7	0.4–1.4	0.365
11–15	0.6	0.4–1.1	0.118	0.6	0.4–1.1	0.133	0.7	0.4–1.3	0.240
on ART (Yes)									
No	0.3	0.1–0.9	0.036	–	–	–	–	–	–
Viral load < 200 copies/ml (No)									
Yes	–	–	–	3.2	1.5–6.8	0.002	–	–	–
Adherence (optimal)									
Suboptimal/ Very bad	–	–	–	0.5	0.3–0.8	0.006	0.4	0.2–0.8	0.009

aOR Adjusted odds ratio, 95% CI Confidence interval 95%, PLHIV People living with HIV, ART antiretroviral treatment, MSM Men who have sex with men, PWID People who injected drugs, Reference categories are in brackets

diagnosis less than 2 years ago was associated with worse self-rated health. One possible explanation for this finding lies in the fact that being diagnosed with HIV infection has been considered a stressful life event with psychological consequences such as depressive and anxiety symptoms [37]. Worries about confidentiality, disclosure, discrimination or stigma, and fear of infecting others, have been described as main stressors among newly HIV diagnosed [38]. Interventions for detecting and reducing stress among recently diagnosed PLHIV will contribute to improve self-rated health.

Being on ART has been associated with better perceived health [28], highlighting the benefits of treatment beyond the clinical and immunological level. Among PLHIV on ART, a suppressed viral load has also been linked to good/very good self-rated health; a better virological status has been related to better physical and mental health [8, 32], although other studies have not found this association [34]. There is more consensus on the relationship between adherence to ART and QoL [8, 39–41]. In our study, poor adherence was related to worse self-rated health among PLHIV on ART and those that were virally suppressed. Improving adherence has benefits not only in slowing disease progression and decreasing mortality, but also in increasing the well-being of PLHIV.

This study has some limitations. Firstly, not all regions in Spain have participated in this information system and results cannot be extrapolated to the whole country. Secondly, participation of hospitals was voluntary, although population coverage regarding population in participating regions was high. Thirdly, patients who attended hospitals more regularly or those who were more seriously ill could be overrepresented; under this hypothesis, prevalence of good or very good self-rated health in this study would be underestimated. Fourthly, many different individuals performed data collection, making it difficult to control reproducibility and data quality. To prevent bias, a common questionnaire and standard procedures were developed. Fifthly, self-rated health is a subjective measure and was difficult to compare with general or specific scales to evaluate HQoL. However, self-perceived health is a multidimensional construction that includes not only health problems but also coping and well-being attitudes. Finally, some important variables that affect HQoL such as depression or anxiety were not included in the EH at the time of the study.

On the other hand, our study also has several strengths. It is population-based, allowing all PLHIV who attend HIV care in the catchment areas of the participating centers to be included. In Spain, ART is available only in hospital pharmacy services and therefore the vast majority of HIV-infected patients receive HIV

care and treatment in public hospitals. Inclusion criteria collect both new HIV diagnoses and patients diagnosed many years ago, providing an overall picture of PLHIV in Spain. Furthermore, the use of the same question of self-rated health than in the National Health Survey allowed for comparison with the general population. This new variable has been well accepted by participants, as indicated by the low number of missing data. Last but not at least, including a self-rated health question in a consistent information system will allow us to include a proxy of HQoL as part of routine monitoring of PLHIV.

Conclusions

Nearly seven in 10 participants in this study considered their health status as good or very good; this figure was lower than in the general population in Spain, even among PLHIV who were virally suppressed. Both demographic and clinical determinants had an impact on quality of life.

Prevalence of very good/good self-rated health increased among PLHIV on ART and among those virally suppressed. Measuring this indicator only in the last subgroup does not take into account HIV-infected people who not receiving ART and those on ART with unsuppressed viral load; these two groups perceived having poorer health. This finding suggested that evaluating self-rated health as a proxy of the fourth 90 only among virally suppressed PLHIV could provide overestimated results.

Abbreviations

AIDS: Acquired immunodeficiency syndrome; ART: Antiretroviral treatment; HRQoL: Health-related quality of life; MSM: Men who have sex with men; PLHIV: People living with HIV; PWID/Ex-PWID: People who had ever injected drugs

Acknowledgements

We acknowledge health professionals and patients participating in the Hospital survey of patients infected with HIV. We would like to thank Dr. Julia del Amo for constructive criticism of the manuscript and Nuria Gallego for English review.

Members of the Hospital Survey Study Group, 2019.

-Aragón: M Egidio (H.G. San Jorge, Huesca); S Letona (H.C.U. Lozano Blesa, Zaragoza).
 -Asturias: MC Royo (DG de Salud Pública, Consejería de Sanidad. Oviedo), V Asensi (H.U. Central de Asturias, Oviedo), E García (H. de Jove, Gijón); J Lobo (H. Valle del Nalón, Langreo); MA Meana (H. Álvarez Buylla, Mieres); M de Zárraga (H. San Agustín, Aviles), P Abad (H. Oriente de Asturias, Arriondas); M Álvarez (H. de Jario, Coaña); R Suárez del Villar (H. Carmen y Severo Ochoa, Cangas de Narcea).
 -Balears: MG Jaume Amengual (Conselleria de Salut, DG de Salut Pública i Participació); A Rey (F.H. Comarcal de Inca, Inca); A Payeras (H. Son Llatzer, Palma de Mallorca); M Riera (H. Son Espases, Palma de Mallorca); L Vilaplana (H. Manacor, Manacor); E Rodríguez de Castro (H. Mateu Orfila, Mahón); R Canet (H. Can Misses, Ibiza).
 -Canarias: E Colino (C.H.U. Materno-Insular Infantil, Las Palmas de Gran Canaria); MA Cárdenas (C.H. Dr. Negrín, Las Palmas de Gran Canaria); JL Gómez (C.H.U. de Canarias, San Cristóbal de la Laguna, Tenerife); J Gómez (H.U. Ntra Sra. de la Candelaria, Santa Cruz de Tenerife); JF Lluch (H. Dr. José Molina Orosa, Arrecife).
 -Cantabria: MC Fariñas (H.U. Marqués de Valdecilla, Santander).

-Castilla-La Mancha: E Martínez (C.H.U. de Albacete, Albacete); MI García (H.G. de Almansa, Almansa); H Portillo (C.H. de Ciudad Real, Ciudad Real); JR Barbera (H. General La Mancha-Centro, Alcazar de San Juan); C Pereda (H. Santa Bárbara, Puertollano); G López (H. General de Tomelloso, Tomelloso); MP Geijo (H. Virgen de la Luz, Cuenca); F Cuadra (H. Virgen de la Salud, Toledo); M Torralba (HGU de Guadalajara, Guadalajara); JM Yzusuqui (H. Nuestra Señora del Prado, Talavera de la Reina).

-Castilla y León: MA Garcinuño (H. Ntra. Sra. de Sonsoles, Ávila); M Sánchez (H. Santiago Apóstol, Miranda de Ebro); P Cancelo (H. Santos Reyes, Aranda de Duero); J Locutura (C.A. Universitario de Burgos, Burgos); JA Carro (C.A. de León, León); A Bahamonde (H. del Bierzo, Ponferrada); Y Morán, J Sánchez (C.A. Universitario de Palencia, Palencia); A Iglesias (C.A. de Salamanca, Salamanca); EM Ferreira (C.H. de Segovia, Segovia); M del Valle (C.A. de Soria, Soria); C. Hinojosa (H.C.U. Valladolid); P Bachiller (H. U. Rio Hortega, Valladolid); A Chocarro (C.A. Zamora, Zamora).

-Ceuta: D Navarro (H.U. de Ceuta, Ceuta).

-Comunidad Valenciana: L. Mitjans (Dirección General de Salud Pública. Conselleria de Sanitat Universal y Salud Pública); J Portilla (H.G.U. de Alicante, Alicante); MJ Esteban (H. Virgen de los Lirios, Alicante); M. Masía (H.G.U. de Elche, Elche); A Belso (H.G.U. de Elda, Elda); J Llenas (H. del S.V.S Vega Baja, Orihuela); F Pasquau (H. Marina Baixa, Villajoyosa); J Uro (H.G. de Castellón, Castellón); V Chabrera (H. Comarcal La Plana, Villareal); M García (C.H.U. de Valencia, Valencia); MJ Galindo (H.C.U. de Valencia, Valencia); M Salavert (H. U. La Fe, Valencia); JM Querol (H. Francisc de Borja, Gandía); T Labrador, C Belenguer, J Argente (H. Lluís Alcanyis, Xativa); MJ Garcia (H.U. de Torreveja, Torreveja); M Fernández (H. de Manises, Manises).

-Extremadura: MN Nogales (H. Universitario de Badajoz, Badajoz); M Galán (H. Don Benito-Villanueva de la Serena, Don Benito); M Medina (H. de Mérida, Mérida); S Trejo (H. Campo Arañuelo, Navalalmoral de la Mata); C Martín (C.H. Universitario de Cáceres, Cáceres); C García (H. Virgen del Puerto, Plasencia); I Montes (H. de Coria, Coria).

-La Rioja: JA Oteo (C.H. San Millán-San Pedro, Logroño).

-Comunidad de Madrid: F Pulido (H. Doce de Octubre, Madrid); M. Górgolas, A. Cabello (F. Jiménez Díaz, Madrid); JC López Bernaldo de Quirós (H.G.U. Gregorio Marañón, Madrid); J Sanz (H. La Princesa, Madrid); MJ Pérez (H. Ramón y Cajal, Madrid); I Suárez-García (H. Infanta Sofía, San Sebastian de los Reyes); MT Fernández (H. del Sureste, Arganda del Rey); JL Pérez (H.U. Infanta Cristina, Parla); JE Losa (F.H. Alcorcón, Alcorcón).

-Melilla: A Fernández (H. Comarcal de Melilla, Melilla).

-Murcia: C Galera, H Albendín (H.U. Virgen de la Arrixaca, El Palmar); G Alonso (H. Rafael Méndez, Lorca); D Piñar (H. Los Arcos del Mar Menor, San Javier); OJ Martínez (H.G.U. Santa Lucía, Cartagena); A Cano (H.G.U. Reina Sofía, Murcia); J Bravo (H. Morales Meseguer, Murcia).

-País Vasco: A Arrillaga (Plan del sida del País Vasco); JA Iribarren (H.U. Donostia, San Sebastián); JJ Portu (H.U. Araba, Vitoria).

Authors' contributions

AD was the main study researcher. She supervised field work, wrote the statistical analysis plan and the final version of the manuscript. MRA performed data collection and management, quality control, wrote the first version of the manuscript and reviewed all the manuscript drafts. VH made important contributions to successive versions of the manuscript. HM, GG1, MOL, MAP, GG2, AI, LJV, IL, EM, DC, RA, MAB, IA-G, AA were the staff responsible for coordinating the survey in the autonomous regions. They participated in development of the study protocol, supervised field work and estimated the population coverage. They have critically reviewed all versions of the manuscript. MJP-E, JCL-B, FP, MG, JS, IS-G, MTF, JEL, JLP and the Hospital Survey Study Group were the clinicians responsible for patient recruitment the participating hospitals and performed field work in their hospitals. They have reviewed all versions of the paper. All authors have seen and approved the final manuscript.

Funding

None.

Availability of data and materials

The dataset analysed during the current study is only available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was performed in accordance with the requirements of the Spanish legislation on data protection. Questionnaires were totally anonymous, i.e. no personal identifiers were collected and linkage of questionnaires to patients was not possible. Informed consent for epidemiological surveillance data is deemed unnecessary according to national regulations (Ley 33/2011, de 4 de octubre, General de Salud Pública, Article 41. BOE-A-2011-15623). The Ethics Committee of Hospital Puerta de Hierro approved this study in 2014 (Acta nº 301).

Consent for publication

Not applicable.

Competing interests

None.

Author details

¹Unidad de vigilancia de VIH, ITS y hepatitis, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, C/ Monforte de Lemos, 5, 28029 Madrid, Spain. ²Servicio de Vigilancia Epidemiológica y Enfermedades Transmisibles, DG de Salud Pública, Consejería de Sanidad, Valladolid, Castilla y León, Spain. ³Servicio de Epidemiología, DG de Salud Pública, Consejería de Sanidad, Toledo, Castilla-La Mancha, Spain. ⁴Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, Spain. ⁵Servicio de Enfermedades Infecciosas, Hospital Universitario Gregorio Marañón, Madrid, Spain. ⁶Unidad VIH, Hospital Universitario 12 de Octubre. imas12.UCM, Madrid, Spain. ⁷Unidad de Enfermedades Infecciosas y VIH, Fundación Jiménez Díaz, Madrid, Spain. ⁸Unidad de Enfermedades Infecciosas, Hospital Universitario de La Princesa, Madrid, Spain. ⁹Grupo de enfermedades infecciosas, Servicio de Medicina Interna, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain. ¹⁰FIIB HUIS HHEN, Universidad Europea, Madrid, Spain. ¹¹Servicio de Medicina Interna, Hospital del Sureste, Arganda del Rey, Madrid, Spain. ¹²Unidad de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. ¹³Servicio de Medicina Interna, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain. ¹⁴Coordinación de VIH/sida, Servicio de Promoción de la Salud y Prevención de la Enfermedad, D.G. de Salud Pública, Zaragoza, Aragón, Spain. ¹⁵Servicio de Evaluación de la Salud y Programas, DG de Salud Pública, Consejería de Sanidad, Oviedo, Asturias, Spain. ¹⁶Oficina de Coordinación VIH de Extremadura, Servicio de Participación Comunitaria en Salud, DG de Salud Pública, Servicio Extremeño de Salud, Mérida, Extremadura, Spain. ¹⁷Servicio de Epidemiología y Promoción de la Salud, DG de Salud Pública, Servicio Canario de la Salud, Santa Cruz de Tenerife, Canarias, Spain. ¹⁸Sección de Vigilancia Epidemiológica, DG de Salud Pública, Santander, Cantabria, Spain. ¹⁹Servicio de Prevención y Epidemiología del Plan sobre sida, Consejería de Sanidad y Consumo, Ceuta, Spain. ²⁰Sección de Vigilancia Epidemiológica y Control de Enfermedades Transmisibles, DG de Salud Pública y Consumo, Logroño, La Rioja, Spain. ²¹Servicio de Epidemiología, DG de Sanidad y Consumo, Consejería de Bienestar Social y Sanidad, Melilla, Spain. ²²Coordinación Autonómica de Drogas y de la Estrategia de Sida, DG de Salud Pública i Consum, Conselleria de Salut, Família i Bienestar Social, Palma de Mallorca, Baleares, Spain. ²³Servicio de Promoción y Educación para la Salud, Dirección General de Salud Pública y Adicciones, Consejería de Salud, Murcia, Región de Murcia, Spain. ²⁴Servicio Promoción de la Salud y Prevención en la Etapas de la Vida, Dirección General de Salud Pública y Adicciones, Conselleria de Sanitat Universal i Salut Pública, Valencia, Comunidad Valenciana, Spain. ²⁵Programas de Salud, Dirección General, Osakidetza, San Sebastian, País Vasco, Spain.

Received: 23 September 2020 Accepted: 17 January 2021

Published online: 30 January 2021

References

- Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. *Lancet*. 2013;382(9903):1525–33 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673613618097>. Cited 2020 Jun 30.
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. *N Engl J Med*. 2011;365(6):493–505 Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa1105243>. Cited 2020 Jun 30.

3. UNAIDS. 90-90-90. An ambitious treatment target to help end the AIDS epidemic: UNAIDS; 2014. Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed 30 June 2020.
4. Global Health Sector Strategy on HIV 2016–2021. 2016. 60. World Health Organization; Available from: <http://apps.who.int/iris/bitstream/10665/246178/1/WHO-HIV-2016.05-eng.pdf?ua=1>. Accessed 30 June 2020.
5. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo VJ, et al. Beyond viral suppression of HIV – the new quality of life frontier. *BMC Med*. 2016;14(1):94 s12916-016-0640-4. Available from: <http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0640-4>. Cited 2020 Jun 30.
6. Cooper V, Clatworthy J, Harding R, Whetham J, Emerge Consortium. Measuring quality of life among people living with HIV: a systematic review of reviews. *Health Qual Life Outcomes*. 2017;15(1):220 Available from: <https://hqlq.biomedcentral.com/articles/10.1186/s12955-017-0778-6>. Cited 2020 Jun 30.
7. Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. *Lancet HIV*. 2014;1(1):e32–40 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2352301814700189>. Cited 2020 Jun 30.
8. Fuster-Ruiz de Apodaca MJ, Laguía A, Safreed-Harmon K, Lazarus JV, Cenoz S, del Amo J. Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF. *Health Qual Life Outcomes*. 2019;17(1):144 Available from: <https://hqlq.biomedcentral.com/articles/10.1186/s12955-019-1208-8>. Cited 2020 Jun 30.
9. Crane HM, Rompaey SEV, Dillingham PW, Herman E, Diehr P, Kitahata MM. A Single-Item Measure of Health-Related Quality-of-Life for HIV-Infected Patients in Routine Clinical Care. *AIDS Patient Care STDs*. 2006;20(3):161–74 Available from: <http://www.liebertpub.com/doi/10.1089/apc.2006.20.161>. Cited 2020 Jun 30.
10. Safreed-Harmon K, Anderson J, Azzopardi-Muscat N, Behrens GMN, d'Arminio Monforte A, Davidovich U, et al. Reorienting health systems to care for people with HIV beyond viral suppression. *Lancet HIV*. 2019;6(12):e869–77 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2352301819303340>. Cited 2020 Dec 22.
11. Bonner WIA, Weiler R, Orisatoki R, Lu X, Andkhoie M, Ramsay D, et al. Determinants of self-perceived health for Canadians aged 40 and older and policy implications. *Int J Equity Health*. 2017;16(1):94 Available from: <http://equityhealth.biomedcentral.com/articles/10.1186/s12939-017-0595-x>. Cited 2020 Jun 30.
12. Jylhä M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. *Soc Sci Med*. 2009;69(3):307–16 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0277953609002925>. Cited 2020 Jun 30.
13. European Health Interview Survey (EHIS). Available from: <https://ec.europa.eu/eurostat/web/microdata/european-health-interview-survey>. Accessed 30 June 2020.
14. Croezen S, Burdorf A, van Lenthe FJ. Self-perceived health in older Europeans: Does the choice of survey matter? *Eur J Pub Health*. 2016;26(4):686–92 Available from: <https://academic.oup.com/eurpub/article-lookup/doi/10.1093/eurpub/ckw017>. Cited 2020 Jun 30.
15. Kall M, Kelly C, Auzenbergs M, Delpech V. Positive voices: the National Survey of people living with HIV - findings from the 2017 survey [Internet]. London: Public Health England; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/857922/PHE_positive_voices_report_2019.pdf
16. Le Coeur S, Desesquelles A, Morand E, Kanabkaew C, Lelièvre E. Self-rated health among HIV-infected people receiving treatments in Thailand. *Asian Soc Sci*. 2017;1(13):20–30 Available from: <http://hdl.handle.net/20.500.12204/AWRHwtvjgpbz89Adag4RL>.
17. de Souza Junior PRB, Szwarcwald CL, Castilho EA d. Self-rated health by HIV-infected individuals undergoing antiretroviral therapy in Brazil. *Cad Saúde Pública*. 2011;27(suppl 1):s56–66 Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2011001300007&lng=en&tlng=en. Cited 2020 Jun 30.
18. Lazarus JV, Safreed-Harmon K. Depicting a new target for the HIV response: how do you see the “fourth 90”. 2018. Available from: <https://www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/visually-depicting-a-new-target-for-the-hiv-response-how-do-you-see-the-fourth-90-5511380/0>
19. UNAIDS. UNAIDS DATA 2020. 2020. Available from: <https://www.unaids.org/en/resources/documents/2020/unaids-data>
20. Unidad de vigilancia del VIH, ITS y hepatitis. Actualización del Continuo de Atención del VIH en España, 2017–2019. Madrid: Centro Nacional de Epidemiología – Instituto de Salud Carlos III / Plan Nacional sobre el Sida – Dirección General de Salud Pública; 2020. 2020. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/ESTIMACION_DEL_CONTINUO_DE_ATENCION_DEL_VIH_EN_ESPANa_Nov2020.pdf
21. Fumaz CR, Larrañaga-Eguilegor M, Mayordomo-López S, Gómez-Martínez S, González-García M, Ornellas A, et al. Health-related quality of life of people living with HIV infection in Spain: a gender perspective. *AIDS Care*. 2019;31(12):1509–17 Available from: <https://www.tandfonline.com/doi/full/10.1080/09540121.2019.1597959>. Cited 2020 Dec 29.
22. Diez M, Díaz A, Garriga C, Pons M, Ten A, Marcos H, et al. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. *Euro Surveill*. 2014;19(20):20805 Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20805>. Cited 2020 Jun 30.
23. Encuesta Nacional de Salud de España 2017 (ENSE 2017) [Internet]. Ministerio de Sanidad, Consumo y Bienestar Social; Available from: https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2017/ENSE17_pres_web.pdf. Accessed 30 June 2020.
24. Mabaso MLH, Zungu NP, Rehle T, Moyo S, Jooste S, Zuma K. Determinants of excellent/good self-rated health among HIV positive individuals in South Africa: evidence from a 2012 nationally representative household survey. *BMC Public Health*. 2018;18(1):198 Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-5102-9>. Cited 2020 Dec 22.
25. Zeluf-Andersson G, Eriksson LE, Schönnesson LN, Höijer J, Måneshall P, Ekström AM. Beyond viral suppression: the quality of life of people living with HIV in Sweden. *AIDS Care*. 2019;31(4):403–12 Available from: <https://www.tandfonline.com/doi/full/10.1080/09540121.2018.1545990>. Cited 2020 Dec 22.
26. Campos LN, César CC, Guimarães MDC. Quality of life among HIV-infected patients in Brazil after initiation of treatment. *Clinics*. 2009;64(9) Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-593200900900007&lng=en&nrm=iso&tlng=en. Cited 2020 Jun 30.
27. Ventura Cerdá JM. Adherencia, satisfacción y calidad de vida relacionada con la salud en pacientes infectados por el. *Farm Hosp*. 2014;(4):291–9 Available from: <https://doi.org/10.7399/fh.2014.38.4.7404>. Cited 2020 Jun 30.
28. Degroote S, Vogelaers D, Vandijck DM. What determines health-related quality of life among people living with HIV: an updated review of the literature. *Arch Public Health*. 2014;72(1):40 Available from: <https://archpublichealth.biomedcentral.com/articles/10.1186/2049-3258-72-40>. Cited 2020 Jun 30.
29. Rueda S, Raboud J, Mustard C, Bayoumi A, Lavis JN, Rourke SB. Employment status is associated with both physical and mental health quality of life in people living with HIV. *AIDS Care*. 2011;23(4):435–43 Available from: <https://www.tandfonline.com/doi/full/10.1080/09540121.2010.507952>. Cited 2020 Jun 30.
30. Milloy M-J, Marshall BDL, Montaner J, Wood E. Housing Status and the Health of People Living with HIV/AIDS. *Curr HIV/AIDS Rep*. 2012;9(4):364–74 Available from: <http://link.springer.com/10.1007/s11904-012-0137-5>. Cited 2020 Jun 30.
31. Passos SMK, Souza LD de M. An evaluation of quality of life and its determinants among people living with HIV/AIDS from Southern Brazil. *Cad Saúde Pública*. 2015;31(4):800–14 Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2015000400800&lng=en&tlng=en. Cited 2020 Jun 30.
32. Ruiz Perez I, Rodríguez Baño J, Ruz López MA, Jimenez del Arco A, Prados M, Liaño Pasquau J, et al. Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors. *Qual Life Res*. 2005;14(5):1301–10 Available from: <http://link.springer.com/10.1007/s11136-004-4715-x>. Cited 2020 Jun 30.
33. Rodríguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, et al. Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life. *AIDS Patient Care STDs*. 2013;27(1):5–16 Available from: <http://www.liebertpub.com/doi/10.1089/apc.2012.0329>. Cited 2020 Jun 30.
34. George S, Bergin C, Clarke S, Courtney G, Codd MB. Health-related quality of life and associated factors in people with HIV: an Irish cohort study. *Health*

- Qual Life Outcomes. 2016;14(1):115 Available from: <http://hqlo.biomedcentral.com/articles/10.1186/s12955-016-0517-4>. Cited 2020 Dec 31.
35. Knobel H, Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Palacios R, et al. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. *Enfermedades Infecc Microbiol Clín*. 2019;37(6):373–9 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0213005X18302799>. Cited 2020 Jun 30.
36. McGowan J, Sherr L, Rodger A, Fisher M, Miners A, Anderson J, et al. Age, time living with diagnosed HIV infection, and self-rated health. *HIV Med*. 2017;18(2):89–103 Available from: <http://doi.wiley.com/10.1111/hiv.12398>. Cited 2020 Jun 30.
37. Garrido-Hernansaiz H, Alonso-Tapia J. Associations Among Resilience, Posttraumatic Growth, Anxiety, and Depression and Their Prediction From Stress in Newly Diagnosed People Living With HIV. *J Assoc Nurses AIDS Care*. 2017;28(2):289–94 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S105532901630214X>. Cited 2020 Dec 31.
38. Huang Y, Luo D, Chen X, Zhang D, Huang Z, Xiao S. HIV-Related Stress Experienced by Newly Diagnosed People Living with HIV in China: A 1-Year Longitudinal Study. *Int J Environ Res Public Health*. 2020;17(8):2681 Available from: <https://www.mdpi.com/1660-4601/17/8/2681>. Cited 2020 Dec 31.
39. Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, et al. Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study. *J Int AIDS Soc*. 2013;16(1):18643 Available from: <http://doi.wiley.com/10.7448/IAS.16.1.18643>. Cited 2020 Dec 31.
40. Ruiz-Pérez I, de Labry-Lima AO, López-Ruz MÁ, del Arco-Jiménez A, Rodríguez-Baño J, Causse-Prados M, et al. Estado clínico, adherencia al TARGA y calidad de vida en pacientes con infección por el VIH tratados con antirretrovirales. *Enfermedades Infecc Microbiol Clín*. 2005;23(10):581–5 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0213005X05750369>. Cited 2020 Dec 31.
41. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. *AIDS Care*. 2005;17(1):10–22 Available from: <https://www.tandfonline.com/doi/full/10.1080/09540120412331305098>. Cited 2020 Jun 30.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

